The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
The ANDROMEDA study was a phase 3 trial comparing bortezomib, cyclophosphamide, and dexamethasone therapy with daratumumab as an add-on therapy in patients with light chain amyloidosis.
The APOLLO study was a phase 3 trial comparing pomalidomide and dexamethasone therapy with daratumumab as an add-on therapy in patients with relapsed or refractory multiple myeloma who were refractory to...
The researchers conducted 2 studies to test the oral, small-molecule, next-generation sickle hemoglobin inhibitor would safely and substantially reduce erythrocyte hemolysis and increase hemoglobin.
In children with sickle cell disease, transcranial Doppler (TCD) can reveal the importance of higher hemoglobin levels, according to data presented at the American Society of Hematology’s 2021 Annual...
